Asset Dedication’s Phaxiam Therapeutics PHXM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-400
Closed -$1K – 1235
2024
Q1
$1K Hold
400
– – ﹤0.01% 969
2023
Q4
$2K Hold
400
– – ﹤0.01% 918
2023
Q3
$2K Hold
400
– – ﹤0.01% 917
2023
Q2
$3K Hold
400
– – ﹤0.01% 852
2023
Q1
$4K Hold
400
– – ﹤0.01% 793
2022
Q4
$1K Hold
400
– – ﹤0.01% 977
2022
Q3
$2K Buy
+400
New +$3.96K ﹤0.01% 855

Asset Dedication's PHXM Position: Q2 2024 in Review

Asset Dedication sold out of Phaxiam Therapeutics (PHXM) in Q2 2024, closing a stake of 400 shares — an estimated $1K sold.

Asset Dedication first reported a position in PHXM in Q3 2022 and held it in 7 quarters. The position peaked at $4K in Q1 2023. 0 funds tracked by Wall St. Rank hold PHXM as of Q2 2024.

  • Asset Dedication reported no remaining Phaxiam Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Asset Dedication sold 400 Phaxiam Therapeutics shares in Q2 2024, an estimated $1K.
  • Asset Dedication first reported a position in Phaxiam Therapeutics in Q3 2022 and held it in 7 quarters.
  • Asset Dedication's Phaxiam Therapeutics position peaked at $4K in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Phaxiam Therapeutics as of Q2 2024.

Based on Asset Dedication's 13F filing for Q2 2024, filed 6 Aug 2024.